The meningococcal vaccines market is anticipated to show a good growth rate during the forecast period of 2018-2026. Meningococcal disease is a bacterial infection. It is contagious and transmissible through close contact with an infected person. The symptoms include fever, headache, and rash. It can affect individuals of any age group and can be prevented by vaccination. The meningococcal vaccines are categorized into conjugate vaccines, polysaccharide vaccines, Men B vaccines, and combination vaccines.
Reimmunization to Boost Growth
New Zealand was amidst a meningococcal B epidemic between 1991 and 2007. A vaccine was introduced for the same and many New Zealand citizens received the vaccination. In a new study titled New Zealand Meningococcal Market Research 2019, commissioned by GSK, many parents were unsure whether their children had received vaccination or not. As many children during the vaccination period between 1991 and 2007 were around 5 years of age, the Government of New Zealand is urging individuals aged between 13 and 29 for reimmunization to prevent a spike. Such drives may prove as growth multipliers for the meningococcal vaccine market.
Governments Implementing Various Programs
Due to the growing number of meningococcal disease cases, governments across various countries are coming forward and conducting various drives and initiatives to create awareness among the people for vaccinating to protect against the disease. Furthermore, government support for research and development activities for developing new meningococcal vaccines is also considerably rising.
To Get an Exhaustive Overview about the Competition in Meningococcal Vaccines Market, Request for a Report Brochure at https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1666
As conjugate vaccines show more improvement and have more benefits when compared to other vaccine types, they are expected to boost the sales of the meningococcal vaccines market. For instance, Menveo and Menactra protect from four types of meningococcal bacteria of type A, C, W, and Y. Therefore, the Centre for Disease Control and Prevention (CDC) advises meningococcal conjugate vaccinations for infants, and individuals aged 11 or 12 years.